# Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

> **NCT04425629** · PHASE3 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 10078 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** casirivimab+imdevimab combination therapy

## Key facts

- **NCT ID:** NCT04425629
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-16
- **Primary completion:** 2022-01-21
- **Final completion:** 2022-06-09
- **Target enrollment:** 10078 (ACTUAL)
- **Why stopped:** Emerging SARS-CoV-2 variants impacting susceptibility to study drug
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425629, "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04425629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*